ArticleThe Lancet regional health. Western Pacific2025
A population-based study of cause-specific mortality in First Nations Australians with cirrhosis: impact of cardiometabolic comorbidities and liver disease risk factors.
Article in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multisystem burden in cirrhosis: lessons from a marginalised population.The Lancet regional health. Western Pacific · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver disease is an important contributor to high mortality in First Nations Australians. We describe cause-specific mortality by First Nations status in people with cirrhosis. Methods: Population-based retrospective cohort analysis of all adults with cirrhosis admitted to hospitals in the state of Queensland (2007-2022). Patients (1909 First Nations and 20,584 non-First Nations) were followed from the first admission with cirrhosis until date of death, liver transplant, or 31 December 2022, whichever came first. Multivariable Cox regression and Fine and Gray proportional subhazard models were used to assess differences in mortality according to First Nations status. Findings: During a median follow-up of 6.9 years (IQR 3.5-11.1), 995 (52.1%) First Nations and 11,367 (55.2%) non-First Nations patients died. First Nations people died on average 9.4 years younger than non-First Nations Australians (57.0 years (SD = 12.1) vs 66.4 years (SD = 12.2), respectively). Approximately half of First Nations (48.9%) and non-First Nations (50.4%) deaths had liver disease as their underlying cause, and the 10-year liver-related mortality did not differ according to First Nations status (adjusted-sHR = 0.92, 95% CI 0.83-1.01). First Nations patients had a 1.6-fold increased risk of 10-year mortality due to cardiovascular disease (adjusted-sHR = 1.59, 95% CI 1.29-1.96), diabetes (adjusted-sHR = 1.60, 95% CI 1.07-1.52), and infections/parasitic diseases (adjusted-sHR = 1.61, 95% CI 1.12-2.23) vs non-First Nations patients. Interpretation: Mortality due to cardiovascular disease, diabetes, and infections/parasitic diseases are 60% higher in First Nations Australians with cirrhosis. The higher non-liver disease mortality in First Nations Australians reinforces the need for a holistic approach to management of metabolic comorbidities in patients with cirrhosis. Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.